Book Now GLP-2 30 mg vialdual GIP/GLP-1 receptor agonist for appetite control, glucose support, and weight management
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
329,330 In degenerative joint diseases like OA, the metabolic balance of chondrocytes is disrupted, leading to the overproduction of degrading enzymes and inflammatory mediators, including iNOS, MMP-13, and ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5), which participate in cartilage degradation and inflammatory processes
[1] That said, GLP-1 medications arent cheap
GLP-1 provides systemic metabolic benefits: Reduced Visceral Fat: GLP-1 preferentially mobilizes harmful visceral adiposity (fat around organs), which drives inflammation and cardiometabolic disease
